Alpha Cognition (ACOG) Set to Release Earnings on Wednesday

Alpha Cognition (NASDAQ:ACOG) is expected to post its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect the company to announce earnings of ($0.33) per share and revenue of $7.04 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:30 PM ET.

Alpha Cognition (NASDAQ:ACOG) last issued its earnings results on Thursday, August 13th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.01). The firm had revenue of $6.00 million during the quarter, compared to analyst estimates of $4.38 million. Alpha Cognition had a negative net margin of 153.61% and a negative return on equity of 54.60%. On average, analysts expect Alpha Cognition to post ($1.38) EPS for the current fiscal year and ($0.61) EPS for the next fiscal year.

Alpha Cognition Stock Up 4.0%

Shares of ACOG stock opened at $8.53 on Thursday. Alpha Cognition has a one year low of $4.50 and a one year high of $10.14. The stock has a fifty day moving average price of $8.85 and a 200 day moving average price of $7.19.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ACOG. HC Wainwright boosted their price target on shares of Alpha Cognition from $18.00 to $20.00 and gave the company a “buy” rating in a report on Monday, August 17th. B. Riley Financial initiated coverage on shares of Alpha Cognition in a research note on Thursday, August 20th. They issued a “buy” rating and a $21.00 price objective for the company. Craig Hallum reaffirmed a “buy” rating and set a $17.00 price objective on shares of Alpha Cognition in a report on Friday, August 14th. Wall Street Zen upgraded shares of Alpha Cognition from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, Raymond James Financial started coverage on shares of Alpha Cognition in a research report on Friday, July 10th. They set an “outperform” rating and a $20.00 target price on the stock. Five analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $18.00.

Insider Buying and Selling at Alpha Cognition

In related news, Director Robert Wills acquired 10,000 shares of the stock in a transaction dated Friday, August 21st. The shares were bought at an average cost of $9.62 per share, for a total transaction of $96,200.00. Following the purchase, the director owned 32,241 shares in the company, valued at approximately $310,158.42. This trade represents a 44.96% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 8.60% of the company’s stock.

About Alpha Cognition

Alpha Cognition Inc is a biopharmaceutical company focused on developing and commercializing treatments for neurodegenerative diseases and cognitive disorders. The company’s work is centered on therapies intended to address the medical needs of patients with Alzheimer’s disease and other conditions affecting cognition.

Its lead commercial product is ZUNOVO (galantamine hydrobromide) extended-release capsules, an orally administered treatment approved by the U.S. Food and Drug Administration for mild-to-moderate dementia of the Alzheimer’s type.